REBEL Core Cast 87.0 – Hypercalcemia

Take Home Points

  • Patients with severe hypercalcemia (> 14 mg/dL) are at risk for severe cardiac dysrhythmias and cardiac collapse
  • Treatment centers on volume repletion with normal saline with consideration for the addition of loop diuretics AFTER volume reexpansion is complete
  • As the patient begins to diurese, continually monitor electrolytes

REBEL Core Cast 87.0 – Hypercalcemia

Definition: A serum calcium level > 10.5 mg/dL. 

Background

Causes

  • Malignancy (multiple myeloma, metastases to bone)
  • Granulomatous disease (TB, sarcoidosis)
  • Endocrine (hyperthyroidism, hyperparathyroidism, adrenal insufficiency, pheochromocytoma)
  • Pharmacologic agents (thiazide diuretics, milk-alkali syndrome, PTH therapy for osteoporosis, lithium, Vitamin A)
  • Miscellaneous (Dehydration, rhabdomyolysis, prolonged immobilization, dietary, iatrogenic)
Hypercalcemia with Short QT (via LITFL)

Clinical Manifestations

  • “Stones (renal), Bones (bone pain), Groans (abdominal pain) + Moans (Psychiatric overtones)” 
  • Cardiac Effects 
    • Bradydysrhythmias
    • AV block
    • Sinus Arrest
    • Atrial Fibrillation
    • Ventricular Tachycardia
    • QTc shortening
  • Neuropsychiatric Disorders
    • Major: AMS, seizures, weakness, lethargy, coma
    • Minor: Anxiety, depression, confusion, hallucinations
    • Hyporeflexia

Diagnosis

  • Serum calcium > 10.5 mg/dL
    • 10.5 – 12.0 mg/dL considered moderate
    • > 14 mg/dL considered severe + potentially life-threatening 
  • EKG
    • Short QTc interval (also caused by congenital short QT syndrome and digoxin)
    • Prolonged PR
    • Widened QRS complex
    • AV block

Management

  • Supportive Care – ABCs, IV, O2, Monitor
  • Volume Expansion
    • The majority of patients with hypercalcemia have significant dehydration
    • Normal saline administration
      • Mechanism of action: Corrects volume depleted state and inhibits proximal tubule calcium resorption
      • Monitor other electrolytes (potassium, sodium)
      • Dose
        • Bolus to correct hypotension
        • Careful administration while monitoring overall fluid status (patients often have cardiac and/or renal dysfunction making them susceptible to volume overload)
        • Loop diuretics (i.e. furosemide)
          • Mechanism of action: Inhibits reabsorption of Na,K, Cl via the Na+-K+-2Cl cotransporter in the thick ascending loop of henle, thereby also inhibiting Ca2+ and Mg2+ reabsorption
          • Theoretical benefit of “forced diuresis” not proven in the literature
          • Should NOT be given until volume repletion completed as it can exacerbate hypercalcemia in this situation
  • Bisphosphonates
    • Mechanism of action: inhibit osteoclast-mediated bone resorption
    • Zoledronic acid 
      • Preferred in hypercalcemia in the setting of malignancy
      • Dose: 4 mg IV over 15 minutes
    • Other Agents: Pamidronate, Etidronate
  • Calcitonin
    • Mechanism of action: inhibits Ca2+ absorption in the intestines, inhibits osteoclast activity, stimulates osteoblastic activity, inhibits renal tubular cell reabsorption
    • Dose: 4 IU/kg IM Q12
  • Cinacalcet
    • Mechanism of action: increases the sensitivity of Ca2+ receptors on parathyroid cells to reduce PTH levels and, thus Ca2+ levels
    • Indications: Hypercalcemia in patients with secondary hyperparathyroidism (i.e. CKD on dialysis, parathyroid carcinoma)
  • Other
    • Hemodialysis
    • Parathyroidectomy may be considered in patients with hypercalcemia caused by hyperparathyroidism

Take Home Points

  • Patients with severe hypercalcemia (> 14 mg/dL) are at risk for severe cardiac dysrhythmias and cardiac collapse
  • Treatment centers on volume repletion with normal saline with consideration for the addition of loop diuretics AFTER volume reexpansion is complete
  • As the patient begins to diurese, continually monitor electrolytes

References

Pfenning CL, Slovis CM: Electrolyte Disorders; in Marx JA, Hockberger RS, Walls RM, et al (eds): Rosen’s Emergency Medicine: Concepts and Clinical Practice, ed 8. St. Louis, Mosby, Inc., 2014, (Ch) 125: p 1636-53.

Read More

Post Peer Reviewed By: Salim R. Rezaie, MD (Twitter: @srrezaie)

Cite this article as: Anand Swaminathan, "REBEL Core Cast 87.0 – Hypercalcemia", REBEL EM blog, October 5, 2022. Available at: https://rebelem.com/rebel-core-cast-87-0-hypercalcemia/.

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share via Email

Want to support rebelem?

Sponsored